22 results about "Recombinant antigen" patented technology

This invention discloses an ANXA1 recombinant antigen, its preparation method, and its applications, belonging to the field of biodetection technology. The ANXA1 recombinant antigen of this invention is based on the wild-type ANXA1 protein shown in SEQ ID NO.1, obtained by deleting its first epitope-masking region, thus making the epitope more easily exposed. Verification has shown that, compared to the full-length ANXA1 antigen, the ANXA1 recombinant antigen of this invention has improved sensitivity in early lung cancer detection, and its detection performance is significantly superior to commercially available ANXA1 recombinant antigens. Therefore, the ANXA1 recombinant antigen of this invention provides a new approach for the early auxiliary diagnosis of lung cancer.

This invention provides a recombinant conjugate protein against EBV virus and its application. The recombinant conjugate protein is a conjugate of recombinant protein HBc-SC and recombinant EBV antigen protein. In the recombinant conjugate protein, the molar ratio of recombinant protein HBc-SC to recombinant EBV antigen protein is 1:1 to 1:12. The amino acid sequence of the recombinant protein HBc-SC is shown in SEQ ID NO:1. The recombinant EBV antigen protein includes a recombinant gHgL fragment and a tag sequence. The recombinant gHgL fragment is shown in SEQ ID NO:3. The tag sequence is shown in SEQ ID NO:5, and the tag sequence is located at the C-terminus of the recombinant EBV antigen protein. The recombinant conjugate protein provided by this invention can induce strong humoral immunity, significantly increasing neutralizing antibody titers in epithelial cells and B cells, making it an excellent candidate vaccine for preventing EBV virus infection.

This invention relates to an ELISA detection kit for porcine reproductive and respiratory syndrome virus (PRRSV) based on M-GP5 recombinant protein, and belongs to the field of ELISA detection technology. The kit includes recombinant (M-GP5) antigen protein, an ELISA plate, blocking buffer, primary antibody dilution buffer, enzyme-labeled secondary antibody, secondary antibody dilution buffer, chromogenic solution, stop solution, negative serum, and positive serum. It features high sensitivity, high specificity, and good stability, and can accurately detect PRSV antibodies.

The present invention relates to a test kit for performing an assay to detect and measure at least one autoantibody molecule in a subject developing type 1 diabetes (T1D). The invention more specifically relates to a recombinant antigen molecule fused to a bioluminescent reporter protein to detect an autoantibody molecule against a self-antigen. Said self-antigen is preferably expressed by pancreatic islet beta cells and include insulin, proinsulin, Glutamate decarboxylase 65, islet antigen 2, and Zinc transporter 8. More specifically, the present invention relates to an assay comprising a set of at least three recombinant antigen molecules in a single composition, the antigen molecules being selected from the list comprising recombinant human Glutamate decarboxylase 65, recombinant human islet antigen 2, recombinant human Zinc transporter 8, recombinant human insulin, and recombinant human proinsulin. The invention further relates to methods for determining the presence and / or level of at least one autoantibody molecule in a sample from a human subject developing T1D using said recombinant antigen molecules. According to the invention, the presence, absence, or amount of one or more autoantibody molecules against said self-antigens is determined with a luciferase immune precipitation system (LIPS) assay or a modified version of a LIPS assay, i.e., a solid phase capture LIPS (scLIPS) assay.

The application discloses a kind of modular serum-free cell culture medium and its application, belong to biomedical technology field.The culture medium includes: epidermal growth factor, recombinant insulin, cholesterol-phospholipid nanoparticles, beta-mercaptoethanol, pluronic F-68, glucose / glutamine, trace element mixed solution.The modular serum-free cell culture medium provided by the application can not only meet the large-scale culture of stem cells, but also be used for the industrial production of in vitro diagnostic reagent raw materials such as recombinant antigen, viral vector, recombinant protein and monoclonal antibody, with wide cell adaptability, low production cost, significant economy, stable process, and strict requirements of FDA / EMA for biological products.

The present invention relates to a novel recombinant antigen protein for Japanese encephalitis and, more specifically, to a recombinant antigen protein for Japanese encephalitis, designed through protein structural stability analysis and introduction of point mutations. It has been identified that a composition comprising the recombinant antigen protein for Japanese encephalitis, according to the present invention, exhibits immunogenicity and protective efficacy against challenge inoculation that are superior to those of an approved live-attenuated vaccine. In particular, it has been experimentally identified that the recombinant antigen protein for Japanese encephalitis, of the present invention, exhibits excellent protective efficacy against Japanese encephalitis virus G5 and other genotypes. Therefore, the recombinant antigen protein for Japanese encephalitis, of the present invention, can be variously used in the field of preventing infection by Japanese encephalitis virus G1 to G5.

This invention discloses a kit for the quantitative detection of C-reactive protein (CRP) in giant pandas and its application, belonging to the field of biodetection technology. The kit disclosed in this invention comprises reagent R2 with the following concentrations: 50 mM PBS pH 7.5, Tween-20 6 ml / L, 270 nm polystyrene carboxylated latex 2.5 g / L, sucrose 30 g / L, BSA 10 g / L, rabbit anti-giant panda CRP polyclonal antibody 6.75 mg / L, and preservative 0.5 ml / L. The rabbit anti-giant panda CRP polyclonal antibody is obtained by immunizing giant white rabbits with the recombinant antigen expressed by the sequence shown in SEQ ID NO. 4. This invention provides a highly efficient, simple, low-cost, and scalable detection method.

This invention relates to the field of immunodiagnostics and provides recombinant HIV antigens for HIV antibody detection. Specifically, it concerns recombinant HIV antigens, nucleic acid molecules, expression vectors, host cells, reagents, kits, and their use. When recombinant HIV antigen proteins are used as the labeling end, the marker activity of the recombinant HIV antigen can be significantly improved, and nonspecific immunobinding activity can be reduced, thereby increasing sensitivity.

The application discloses a plant-expressed varicella-zoster virus gB recombinant antigen and a preparation method, product and application thereof, and belongs to the technical field of plant molecular biology and vaccine engineering. The technical problems to be solved are that the existing VZV gB protein has low heterologous expression, poor stability and insufficient antigen activity; the existing VZV vaccine has high production cost, is difficult to popularize and has a single antigen with an immune escape risk; and the plant expression system is not mature in VZV gB antigen production, and lacks a complete preparation scheme and related products. The technical solution is that the natural VZV gB protein is modified, a furin protease cleavage site is knocked out, and a H527P mutation is introduced, related nucleic acid molecules, vectors and plant source cells are constructed, high-activity antigens are obtained through culture and purification, and the high-activity antigens are applied to the preparation of VZV drugs / vaccines, and have the advantages of low cost, high safety and strong immunogenicity.

The application provides a hepatitis C antibody detection antigen composition and application, kit and detection method thereof, relates to the antibody detection technical field, and the hepatitis C antibody detection antigen composition comprises a labeled recombinant antigen and a coated recombinant antigen, the amino acid sequence of the labeled recombinant antigen includes Trx and hepatitis C Core region, NS3 protein, NS4b protein dominant epitope and His tag, and the full-length sequence is shown as SEQ ID NO. 1. The labeled recombinant antigen used in the application is obtained by mutating 7 cysteines (C) into alanine (A) by amino acid mutation on the NS3 protein, reducing the aggregation and precipitation caused by disulfide bond of the recombinant protein, and improving the protein stability. When colloidal gold is used for antigen labeling, a secondary indirect labeling method is adopted, which is beneficial to the exposure of antigen epitopes, can improve the reaction sensitivity, and reduces the antibody missed detection.

This invention provides a nanoparticle protein, MntC-rePO@LS, its preparation method, and its applications. This protein is formed by the covalent binding of MntC@LS and recombinant V antigen-outer membrane protein OprI (rePO) via heteropeptide bonds, creating a dual-nanoparticle vaccine molecule. The recombinant protein SpyCatcher-MntC@LS of this invention can be induced to express in soluble form in *E. coli* and can bind efficiently to the recombinant protein rePO-SpyTag under mild conditions. The nanoparticle protein of this invention can induce a high level of immune response in animals, exerting an immunoprotective effect. Experiments show that its rate of antibody response induction and protective efficiency are significantly superior to those of monomeric MntC, monomeric rePO, and their physical mixtures, and it can be used for the prevention and treatment of *Pseudomonas aeruginosa* and / or *Staphylococcus aureus* infections.

The invention relates to a diagnostic kit and methods for detecting and quantifying autoantibodies associated with the onset of type 1 diabetes (T1D). The kit comprises recombinant antigen molecules fused to bioluminescent reporter proteins for the detection of autoantibodies directed against self-antigens expressed by pancreatic islet beta cells. The presence, absence, or amount of one or more autoantibody molecules against said self-antigens is determined with a luciferase immune precipitation system (LIPS) assay or a modified version of a LIPS assay, i.e., a solid phase capture LIPS (scLIPS) assay.

The application belongs to the technical field of biological medicine, and provides a tick-borne encephalitis virus vaccine based on bacterial-like particles, a preparation method and application thereof, wherein the tick-borne encephalitis virus vaccine is EDc2&MAB2560-GEM co-display bacterial-like particles, which are prepared by co-displaying recombinant antigen protein TBEV E-DIII-Dcpep2-PA3 and recombinant adjuvant protein MAB2560-PA3 on the surface of GEM particles; the prepared tick-borne encephalitis virus vaccine has good immunogenicity and can induce animals to produce efficient and persistent specific immune responses.

The application discloses a preparation method and application of a recombinant SLO antigen. In the application, a preparation method of the SLO antigen based on genetic engineering technology is developed, a polynucleotide coding the SLO antigen which is optimized based on synonymous codon preference is introduced into a carrier, a prokaryotic expression plasmid is successfully constructed, and the expression amount of the target protein is improved; and through optimization of culture conditions such as a culture medium and a culture temperature, expression of a high proportion of soluble proteins is realized, and the obtained antigen has high activity.

Provided herein are recombinant antigen receptors, for example chimeric antigen receptors (CARs), that comprise modified cytoplasmic domains that provide improved signalling and thereby provide improved performance and safety. Also provided are polynucleotides encoding the recombinant antigen receptors, vectors comprising the polynucleotides, and engineered immune cells comprising the vectors and / or polynucleotides. The invention further provides methods for engineering immune cells to express the recombinant antigen receptors. Improved recombinant antigen receptor signalling is also provided by co-expressing a first recombinant antigen receptor and a second recombinant antigen receptor or co-expressing a recombinant antigen receptor and a protein involved in transducing the signal from the activated recombinant antigen receptor. Also provided are methods of treating a variety of conditions, including, but not limited to, blood cancers and cancers characterized by solid tumors, by administering the engineered cells to patients suffering from such a condition.

The application provides two monoclonal antibodies XJ16 and XJ23 against a recombinant antigen protein membrane surface antigen SAG1 protein of Toxoplasma gondii, the antibodies can specifically recognize Toxoplasma gondii at various stages, have the characteristics of high sensitivity and wide recognition range, can detect Toxoplasma gondii infection at various stages, can be used for detecting the existence and content of Toxoplasma gondii in samples, lays a foundation for exploring Toxoplasma gondii, and provides a new exploration idea for exploring the mechanism of rapid and slow Toxoplasma gondii transformation and then developing new prevention and treatment strategies.

The present application relates to a kind of human bocavirus broad-spectrum recombinant antigen, detection test paper and its preparation and application, to solve the technical problem of lack of simultaneous detection of multiple HBoV genotype antibody fast, simple diagnostic tool in prior art.The core of technical solution is: based on the design of broad-spectrum recombinant antigen (rVP1) of multiple types of common conserved epitope, and it is applied to the construction of colloidal gold immunochromatography test paper.The test paper will be marked in colloidal gold particles as detection probe, by indirect method reaction principle, can realize the synchronous detection of the antibody produced by four main genotypes of HBoV infection in 15-20 minutes.This scheme has the advantages of simple operation, without professional equipment, result is interpreted intuitively, while having good broad-spectrum, sensitivity and specificity, suitable for primary medical institutions rapid screening, field epidemiological investigation and vaccine immune effect evaluation and a variety of application scenarios.

The utility model provides a kind of HCV recombination antigen purification process device, specifically relates to antigen purification field, filler in chromatography column is nickel column filler;The upper and lower sides of interlayer are respectively equipped with water inlet and water outlet;Water inlet is sequentially connected constant-current pump, pre-cooling water bucket by water inlet rubber tube;Water outlet is connected with pre-cooling water bucket by water outlet rubber tube;Protein purification complete system includes conductivity meter, electric ultraviolet light detector, PH detector;Constant-current A pump and constant-current B pump one end are connected with sample A barrel, sample B barrel respectively by import connection pipe, and constant-current A pump and constant-current B pump other end are connected with the liquid inlet of chromatography column by import connection pipe through mixer;The liquid outlet of chromatography column is connected with sample barrel by outlet connection pipe sequentially through conductivity meter, electric ultraviolet light detector, pH detector.The utility model can reduce the tedious operation in experimental process to make test process more succinct, while guaranteeing the production activity and purity of recombination antigen.

This invention belongs to the field of biomedicine, specifically relating to a recombinant antigen combining respiratory syncytial virus (RSV) and influenza A virus, and its application. Based on the F protein of RSVA subtype strains and the HA protein of influenza virus H1N1, this invention obtains a recombinant F protein sequence by removing the post-F-specific I and IV epitope sequences and the shared III epitope sequence between pre-F and post-F. This recombinant F protein then replaces the head region of the influenza virus HA protein, with the two sides connected by linkers to construct an F-HA chimeric protein. It can maintain the pre-F trimer conformation in vivo and in vitro, thereby stimulating the body to produce antibodies specific to the pre-F epitope and possessing high neutralizing activity. Simultaneously, the presence of the stem region of the influenza HA protein provides protection against influenza virus infection. The recombinant antigen of this invention has the advantages of stimulating the body to produce antibodies against both viruses and has the advantage of high yield.

The application relates to a method for labeling an antigen protein with biotin, which comprises the following steps: (1) providing a ligase complex formed by a polypeptide chelated with Ni 2+ and a recombinant TurboID protein; (2) providing a recombinant antigen protein with a HisTag; and (3) reacting the recombinant antigen protein with the HisTag with biotin under the condition that the ligase complex, ATP and Mg 2+ exist to obtain the antigen protein labeled with biotin, wherein the amino acid sequence of the polypeptide in the step (1) is shown in SEQ ID NO: 1, and the amino acid sequence of the recombinant TurboID protein is shown in SEQ ID NO: 2. The method improves the labeling efficiency of the antigen protein labeled with biotin, improves the biotin utilization rate, and improves the positive detection rate of specific antibody detection in a clinical sample.

This invention discloses a method for preparing Brucella antibodies, relating to the field of Brucella antibody preparation technology. Based on one or more combinations of Brucella outer membrane proteins Omp10, Omp19, and BP26, a recombinant antigen is prepared, and the prokaryotic expression codon is optimized. Alpacas are immunized subcutaneously with the recombinant antigen and adjuvant at multiple sites, with booster injections every two weeks for three weeks, to isolate highly active lymphocytes. Total RNA is extracted from the lymphocytes, reverse transcribed to synthesize cDNA, and the VHH gene is specifically amplified by nested PCR to accurately obtain the antibody coding sequence. The VHH gene is cloned into a phage vector, and a high-capacity display library is constructed by electroporation. Solid-phase panning is performed using the recombinant antigen as a target, followed by sequencing to construct a prokaryotic expression vector. Recombinant nanobodies are induced to express, purified by affinity chromatography, and elution conditions are optimized to obtain high-purity, high-yield target proteins. The optimized prokaryotic expression and purification process results in nanobodies with high soluble expression rate, high purification yield, and stable activity, achieving large-scale, low-cost preparation.